Compare CVGI & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CVGI | ATNM |
|---|---|---|
| Founded | 2000 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.7M | 50.2M |
| IPO Year | 2004 | N/A |
| Metric | CVGI | ATNM |
|---|---|---|
| Price | $1.56 | $1.57 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 92.6K | ★ 224.5K |
| Earning Date | 11-10-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $657,532,000.00 | $90,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.32 | $42,943.57 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 11.11 |
| 52 Week Low | $0.81 | $1.03 |
| 52 Week High | $2.59 | $2.41 |
| Indicator | CVGI | ATNM |
|---|---|---|
| Relative Strength Index (RSI) | 44.21 | 63.83 |
| Support Level | $1.52 | $1.37 |
| Resistance Level | $1.67 | $1.54 |
| Average True Range (ATR) | 0.09 | 0.08 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 16.07 | 67.57 |
Commercial Vehicle Group Inc is a provider of systems, assemblies, and components to the commercial vehicle market and the electric vehicle markets. It delivers solutions to complex design, engineering, and manufacturing problems while creating positive change for customers, industries, and communities. Its operating segments are Vehicle Solutions, Electrical Systems, and Aftermarket and Accessories. The company makes the majority of its revenue from Vehicle Solutions. The group generates revenue from its products including seating systems, plastic components, electrical wire harnesses, mirrors, wipers, and other accessories. Its geographic regions are North America, Europe and Asia-Pacific.
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.